Company: CERO
Filing Date: 2025-11-28
Form Type: DEF 14A
Source: 0001213900-25-115783
Chunk: 5

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-28
Form: DEF 14A
Chunk 5
---
 -1236and any other product candidates we may develop for clinical trials and for commercial use, if approved; •the rate and degree of market acceptance of CER -1236and any other product candidates we may develop, as well as the pricing and reimbursement of CER -1236and any other product candidates we may develop, if approved; •our expectations regarding our ability to obtain, maintain, protect and enforce intellectual property protection for CER -1236and for any other product candidate; •our ability to operate our business without infringing, misappropriating or otherwise violating the intellectual property rights of third parties; •our ability to realize the anticipated benefits of any strategic transactions; •our ability to attract and retain the continued service of our key personnel and to identify, hire, and then retain additional qualified personnel and our ability to attract additional collaborators with development, regulatory and commercialization expertise; •our ability to maintain proper and effective internal controls; •the impact of macroeconomic conditions and geopolitical turmoil on our business and operations, including interest rates, inflationary pressures, capital market disruptions, changes in governmental agencies, international tariffs, trade protection measures, economic sanctions and economic slowdowns or recessions; •our expectations regarding the period during which we will qualify as an emerging growth company under the Jumpstart Our Business Startups Act of 2012 and as a smaller reporting company under the federal securities laws; and •our anticipated use of our existing cash, cash equivalents and equity securities. We have based these forward -lookingstatements largely on the Company’s current expectations and projections about the Company’s business, the industry in which we operate and financial trends that we believe may affect the Company’s business, financial condition, results of operations and prospects, and these forward -lookingstatements are not guarantees of future performance or development. These forward -lookingstatements speak only as of the date of this proxy statement and are subject to a number of risks, uncertainties and assumptions described in “ Risk Factors” in the Company’s Annual Report on Form 10 -Kfor the fiscal year ended December 31, 2024 and elsewhere in this proxy statement. Because forward -lookingstatements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward -lookingstatements as predictions of future events. The events and circumstances reflected in the Company’s forward -lookingstatements may not be achieved or occur and actual results could differ materially from those projected in the forward -lookingstatements. Except as required by applicable law, we do not